Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications by unknown
ORIGINAL RESEARCH ARTICLE
Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK)
Rearrangement Presenting as Carcinoma of Unknown Primary
Site: Recognition and Treatment Implications
John D. Hainsworth1 • F. Anthony Greco1
Published online: 10 March 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Molecular cancer classifier assays are being
used with increasing frequency to predict tissue of origin
and direct site-specific therapy for patients with carcinoma
of unknown primary site (CUP).
Objective We postulated some CUP patients predicted to
have non-small-cell lung cancer (NSCLC) by molecular
cancer classifier assay may have anaplastic lymphoma
kinase (ALK) rearranged tumors, and benefit from treat-
ment with ALK inhibitors.
Methods We retrospectively reviewed CUP patients who
had the 92-gene molecular cancer classifier assay (Can-
cerTYPE ID; bioTheranostics, Inc.) performed on tumor
biopsies to identify patients predicted to have NSCLC.
Beginning in 2011, we have tested these patients for ALK
rearrangements and epidermal growth factor receptor
(EGFR) activating mutations, based on the proven thera-
peutic value of these targets in NSCLC. We identified CUP
patients with predicted NSCLC who were subsequently
found to have ALK rearrangements.
Results NSCLC was predicted by the molecular cancer
classifier assay in 37 of 310 CUP patients. Twenty-one of
these patients were tested for ALK rearrangements, and
four had an EML4-ALK fusion gene detected. The diag-
nosis of lung cancer was strongly suggested in only one
patient prior to molecular testing. One patient received
ALK inhibitor treatment and has had prolonged benefit.
Conclusions We report on patients with lung adenocar-
cinoma and ALK rearrangements originally diagnosed as
CUP who were identified using a molecular cancer clas-
sifier assay. Although ALK inhibitors treatment experience
is limited, this newly identifiable group of lung cancer
patients should be considered for therapy according to
guidelines for stage IV ALK-positive NSCLC.
Key Points
Patients with carcinoma of unknown primary who
were predicted to have NSCLC were subsequently
found to have tumors with anaplastic lymphoma
kinase (ALK) rearrangements.
One patient received treatment with ALK inhibitors
and has had prolonged benefit.
This group of patients should be considered for stage
IV ALK-positive NSCLC therapy.
1 Introduction
The identification of specific molecular abnormalities in
individual tumors is integral to the management of patients
with many cancer types. Comprehensive genomic profiling
of tumors is becoming increasingly common, although the
clinical relevance of many of the findings remains unclear.
However, testing for specific molecular abnormalities in
selected cancer types [e.g., human epidermal growth factor
2 (HER2) in breast cancer or gastric/gastroesophageal
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cancer; Kirsten rat sarcoma viral oncogene (KRAS) in
colorectal cancer; v-Raf murine sarcoma viral oncogene
homolog B (BRAF) in melanoma; EGFR and ALK in non-
small-cell lung cancer (NSCLC)] is already a standard part
of clinical practice, since highly active agents are available
for treatment of cancers with these abnormalities [1–6].
Molecular testing is also being incorporated into the
management of patients with CUP. In patients with CUP,
an anatomic primary site cannot be clinically identified,
even though small primary cancers are present and are
usually detectable at autopsy [7, 8]. Molecular cancer
classifier assays, which detect patterns of gene expression
specific to the tissue of origin, can be used on a tumor
biopsy specimen to accurately predict the cancer type or
the primary site in most patients with CUP [9–11]. Clinical
data support the use of site-specific therapy based on these
predictions, rather than traditional empiric chemotherapy
[12–15]. If specific cancers such as breast, colorectal,
gastric, melanoma, or NSCLC are predicted in CUP
patients by molecular cancer classifier assays or immuno-
histochemical (IHC) staining patterns, it seems reasonable
to evaluate these tumors for the same potentially actionable
molecular abnormalities that would be analyzed in their
counterparts with known primary sites. Identification of
such abnormalities could lead to additional effective
treatment options; however, very limited clinical data
currently exist to validate this approach.
In this report, we detail the clinical and pathologic
features of patients with CUP who were predicted to have
adenocarcinoma of the lung by a molecular cancer classi-
fier assay, and subsequently had ALK rearrangements
detected by focused molecular testing.
2 Methods
In this retrospective study, we reviewed records of CUP
patients who had been evaluated with the 92-gene RT-PCR
molecular cancer classifier assay (CancerTYPE ID;
BioTheranostics, Inc.) as part of their diagnostic evalua-
tion. Patients were diagnosed with CUP if an anatomic
primary site was not identified during the following clinical
evaluation: complete medical history, physical examina-
tion, chemistry profile, complete blood counts, computed
tomography (CT) scans of the chest/abdomen/pelvis, serum
PSA level (men), mammograms (women), and further
focused evaluation based on signs/symptoms at presenta-
tion. Routine pathologic evaluation of biopsy specimens
from CUP patients included histologic examination and a
battery of IHC stains (guided by the histology and clinical
features). Since 2008, when our CUP research program
began a systematic evaluation of molecular testing, we
have also performed a molecular cancer classifier assay on
the tumor biopsy specimens of most CUP patients.
The first goal of this review was to identify CUP patients
seen since 2011 who were predicted to have NSCLC by the
92-gene molecular cancer classifier assay [9]. Next, we
identified patients within this group whose cancers had
ALK rearrangements identified by subsequent FISH test-
ing. Since 2011, we have tested for EGFR-activating
mutations and ALK rearrangements whenever feasible in
CUP patients predicted to have NSCLC, following the
demonstration that these molecular abnormalities are
important therapeutic targets in NSCLC [5, 6].
In this report, we review the clinical and pathologic
features of CUP patients who were predicted to have
NSCLC and who were then found to have an ALK
rearrangement.
3 Results
Between May 2011 and May 2015, we evaluated 310 CUP
patients with the 92-gene molecular cancer classifier assay;
37 patients (12 %) were given the diagnosis of NSCLC.
Biopsy specimens from 21 of these 37 patients were tested
for ALK rearrangements and EGFR-activating mutations.
None of the 21 biopsies had EGFR-activating mutations.
The biopsies of four of 21 patients tested (19 %) had ALK
rearrangements (all EML4-ALK). The case histories of
these four patients are detailed below, and are summarized
in Table 1.
3.1 Patient Number 1
This 45-year-old non-smoking African-American female
developed superior vena cava syndrome and was found by
chest CT scan to have large contiguous mediastinal and
right hilar masses, and right pleural effusion. No lung
lesion was seen. Bronchoscopy showed external bronchial
compression but no endobronchial lesions. A medi-
astinoscopy showed a large mediastinal mass; biopsy
revealed metastatic adenocarcinoma, signet ring type. IHC
staining showed CK7?/CK20-; stains for TTF1, ER/PR,
GCDFP, and CDX2 were negative. Since no lung masses
were identified by bronchoscopy or chest CT, the patient
was considered to have CUP, although the clinical pre-
sentation strongly suggested adenocarcinoma of the lung.
Clinical evaluation for extrathoracic metastases revealed
only a 3-cm left adrenal mass.
The patient received treatment with concurrent radiation
therapy and chemotherapy (carboplatin/pemetrexed). The
biopsy specimen was sent for the 92-gene molecular cancer
classifier assay, which indicated the lung as the likely
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tissue of origin (90 % probability). Subsequent FISH test-
ing showed an ALK rearrangement (EML4-ALK).
After completing radiation therapy, she was improved
but had a large residual mediastinal mass. She began
treatment on a clinical trial with the ALK inhibitor crizo-
tinib. She had further regression of the mass, and did well
until she had an isolated brain recurrence 30 months later.
She underwent stereotactic radiosurgery, and continued
ALK inhibitor clinical trial therapy with a next-generation
ALK inhibitor (PF-06463922; Pfizer, Inc.). She has had no
further progression during the last year of therapy, and is
continuing treatment.
Comment This patient is the only one of the four patients
identified who had clinical features (mediastinal/hilar mas-
ses) strongly suggestive of lung cancer, although no endo-
bronchial lesionswere observed at the time of bronchoscopy,
and no discrete lung lesion was present on CT chest scans.
However, the IHC staining (TTF1-) was atypical of lung
adenocarcinoma. Lung adenocarcinomas with signet ring
features have been associated with ALK translocations. She
responded to treatment with ALK inhibitors, and continues
to benefit after[40 months of treatment.
3.2 Patient Number 2
This 52-year-old White male developed cough, chest pain,
and a right flank mass. He had previously smoked cigar-
ettes, but had stopped 10 years previously. Physical
examination showed a firm 5-cm right flank mass. Chest
CT scan showed a 4-cm mediastinal mass, a 3.5-cm pleu-
ral-based mass, and a small right pleural effusion. The right
flank mass was removed, and surprisingly showed blasto-
mycosis infection, for which he received treatment for
1 year with itraconazole. The patient had clinical
improvement, and radiologic findings resolved with the
exception of the mediastinal mass, which slowly enlarged
from 3 cm to 5 cm. Bronchoscopy and head/neck endo-
scopy showed no lesions.
The patient had resection of the mediastinal mass, as
well as biopsy of multiple other mediastinal lymph nodes.
The 5-cm mass showed metastatic poorly differentiated
carcinoma; all other biopsies were negative. IHC studies
included: CK7?/CK20-, TTF1-, human chorionic
gonadotropin (HCG) focally positive, placental alkaline
phosphatase (PLAP) focally positive. The pathology was
reviewed at Indiana University, and additional IHC studies
including human placental lactogen, calretinin, WT-1, and
podoplanin were negative. The tumor histology and overall
IHC staining pattern were not felt to be compatible with a
germ cell tumor. Testicular ultrasound was negative. The
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Biopsy tissue was sent for the 92-gene molecular cancer
classifier assay, which predicted a diagnosis of lung ade-
nocarcinoma (77 % probability). Subsequent FISH testing
showed an ALK rearrangement (EML4-ALK).
Based on the prediction of lung cancer, adjuvant therapy
with four courses of chemotherapy was recommended.
However, the patient declined adjuvant therapy, and has
now been followed for 36 months with no evidence of
recurrence. Treatment with an ALK inhibitor will be rec-
ommended if he develops recurrence in the future.
Comment Although this patient had a mediastinal mass, no
lung lesions were detected on CT scan, at bronchoscopy, or
at thoracotomy. Immunohistochemistry was atypical for
lung adenocarcinoma (TTF1-negative); focally positive
HCG and PLAP stains raised the possibility of a germ cell
tumor but further IHC stains and review by a genitourinary
pathologist did not result in a precise diagnosis. Specific
molecular testing for ALK rearrangement may not have
been considered in the absence of the lung adenocarcinoma
prediction by the molecular cancer classifier assay.
3.3 Patient Number 3
This 26-year-old White female nonsmoker developed right
pelvic pain and was found to have a 6-cm cystic right
ovarian mass. CT of the abdomen/pelvis showed no other
lesions; serum tumor markers included CEA 43, AFP/HCG
normal. She had a laparotomy with right oophorectomy,
which revealed metastatic mucinous adenocarcinoma with
signet ring pattern. Immunohistochemical staining inclu-
ded: CK7?, CK20-, ER/PR-, CD56 -, chromogranin-.
Further clinical evaluation included normal chest CT,
colonoscopy, upper gastrointestinal (UGI) endoscopy, and
mammograms. Positron emission tomography (PET) scan
showed abnormal uptake in the right eighth rib, a medi-
astinal node and a left supraclavicular node. The patient
was given the diagnosis of CUP, with a gastrointestinal
origin considered most likely.
She received six courses of paclitaxel and carboplatin,
followed by local radiation therapy to the right eighth rib
lesion (which had become symptomatic). She did well for
16 months, when she had recurrence in retroperitoneal
lymph nodes. She also developed nephrotic syndrome,
thought possibly to be paraneoplastic. Chest CT scan also
showed a 1.6-cm subcarinal node, a small right hilar node,
and several small indeterminate subpleural nodules in the
left lung. Biopsy of a retroperitoneal node showed meta-
static adenocarcinoma identical to the previous biopsy. A
molecular cancer classifier assay diagnosed lung adeno-
carcinoma as the likely tissue of origin (90 % probability).
In addition, an ALK rearrangement was detected (EML4-
ALK).
At the time of these findings, the patient had already
started second-line therapy with modified FOLFOX-
6 ? bevacizumab, to which she had an objective response
(including resolution of her nephrotic syndrome). She has
remained in remission following completion of treatment.
If relapse occurs in the future, treatment with an ALK
inhibitor will be considered.
Comment This young woman developed symptoms related
to a Kruckenberg tumor, and was found to have metastatic
adenocarcinoma (signet ring features). At presentation, she
had no intrathoracic tumor identified; pathologic evaluation
led to suspicion of a gastrointestinal site of origin. She had
two unusually good responses to empiric therapy for CUP
(paclitaxel/carboplatin and modified FOLFOX6 ? beva-
cizumab, respectively), and remains in remission
44 months after completion of second-line therapy. The
diagnosis of NSCLC was not strongly suggested by clinical
or pathologic features; however, the mucin-producing,
signet ring adenocarcinoma and her non-smoking status are
consistent with ALK-rearranged lung cancer. Treatment
with an ALK inhibitor has not yet been indicated.
3.4 Patient Number 4
This 78-year-old White female developed nausea, weight
loss, and progressive abdominal distension. She had pre-
viously been a cigarette smoker, but had stopped smoking
30 years previously. Chest and abdominal CT scans
showed enlarged mesenteric lymph nodes, a 1.4-cm pre-
tracheal lymph node, and bone lesions (ribs, sternoclavic-
ular joint). A core needle biopsy of the mesenteric node
showed poorly differentiated carcinoma. IHC studies
included AE1/AE3?, CK7?, CK20-, TTF1?. UGI
endoscopy showed two malignant-appearing gastric ulcers,
biopsy of which showed poorly differentiated carcinoma.
Colonoscopy also showed a 2-cm ulcer in the transverse
colon, biopsy positive for poorly differentiated carcinoma.
These ulcers were most consistent with metastases to the
epithelial surfaces. The clinical opinion was that the patient
had CUP with poorly differentiated carcinoma.
Biopsy material was sent for a molecular cancer clas-
sifier assay, which resulted in a prediction of lung adeno-
carcinoma (62 % probability). Subsequent FISH testing
showed ALK rearrangement (EML4-ALK). Unfortunately,
the patient declined all treatment, including a trial of an
ALK inhibitor, primarily due to her poor performance
status. She was referred to hospice for symptomatic care.
Comment This elderly female with a distant history of
smoking cigarettes had a presentation which did not sug-
gest lung cancer. Predominant metastatic sites were in the
abdomen (mesenteric nodes, stomach, colon) and bones.
Although the TTF1 stain was positive, the unusual clinical
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presentation and poorly differentiated histology did not
allow a definitive diagnosis of metastatic lung cancer.
However, the molecular cancer classifier diagnosis and the
ALK rearrangement make an occult primary adenocarci-
noma of the lung very likely.
4 Discussion
We describe several patients who had CUP following
standard clinical and pathologic evaluations. In each case, a
92-gene molecular cancer classifier assay was performed,
and predicted lung adenocarcinoma. The prediction of lung
cancer resulted in further specific molecular testing and the
identification of ALK rearrangements in each tumor. The
patients presented in this report very likely had primary
occult lung adenocarcinomas. The identification of ALK
rearrangements in CUP patients diagnosed as lung adeno-
carcinoma by a molecular cancer classifier assay has not
been previously reported.
Lung cancer has long been recognized as one of the
most common cancer types identified in patients with CUP;
in early autopsy series, occult lung primaries were found in
17–27 % of patients [8, 16]. More recently, NSCLC was
predicted by the 92-gene molecular cancer classifier assay
in 27 of 252 patients (11 %) evaluated and treated in a
multicenter prospective study [12]. In our current review of
310 CUP patients, we found a similar percentage (12 %) of
lung cancer predictions. The incidence of ALK rear-
rangements in CUP patients predicted to have NSCLC
cannot be stated with certainty. Four of our 21 patients
tested (19 %) had ALK rearrangements (seemingly higher
than the 5 % incidence in patients with known NSCLC),
but the small patient numbers preclude definitive conclu-
sions. Also of interest is the fact that none of our 21
patients had EGFR-activating mutations, as compared to a
10 % incidence in patients with known NSCLC. Whether
these findings indicate true differences between these
populations or are related to the small sample size is
unknown.
Without the prediction of the molecular cancer classifier
assay, it is unlikely that the ALK rearrangements in these
four tumors would have been identified. Only in Patient
Number 1 were the clinical features highly suggestive of
NSCLC, although no anatomic primary site was identified
by chest CT scan or bronchoscopy. In the other three
patients, the clinical presentations were not strongly sug-
gestive of lung cancer (two patients had predominant intra-
abdominal disease, and a third, who had a mediastinal
mass, had no lung lesions detected). Likewise, the histo-
logic examination and IHC staining batteries were highly
suggestive of lung adenocarcinoma in only one case. In two
patients, the TTF1 stain was negative (known to be positive
in about 80 % of lung adenocarcinomas). In one patient,
scattered focal staining for HCG and PLAP raised the
possibility of a germ cell tumor, although this diagnosis
was considered unlikely after expert review and additional
IHC stains.
Since none of the patients had an anatomic primary site
found in the lung, the molecular cancer classifier predic-
tions cannot be unequivocally confirmed. However, it is of
interest that the patients exhibited some of the features of
ALK-positive NSCLC: All patients were either never
smokers or had a distant smoking history, and two of the
four patients had signet ring adenocarcinomas, found to be
common in ALK-positive NSCLC [17, 18]. In addition, the
specific ALK rearrangement (EML4-ALK) found in all
four tumors is strongly associated with adenocarcinoma of
the lung.
To date, only one of these four patients has received
treatment with ALK inhibitors. This patient had a partial
response to crizotinib, which persisted for 30 months
before recurrence with an isolated brain metastasis. Fol-
lowing stereotactic radiotherapy, the patient was switched
to an investigational ALK inhibitor, with ongoing disease
stability after 12 additional months of treatment. Two of
the other patients are currently disease-free after previous
treatment, although both remain at risk for relapse. Treat-
ment with ALK inhibitors is probable at the time of
relapse.
Recently, the use of comprehensive molecular profiling
to search for the presence of actionable genetic alterations
has become much more widespread. Since the heteroge-
neous group of CUPs is known to include cancers arising
from a diverse group of occult primary sites, and has pre-
viously been associated with a high number of mutations, it
is predictable that some of these cancers will contain
actionable mutations. In a group of CUPs in which com-
prehensive genomic profiling was performed, at least one
molecular abnormality was identified in 192 of 200 tumors
(96 %) [19]. Molecular alterations targeted by currently
marketed anticancer drugs [HER2, EGFR, BRAF, ALK,
rearranged during transfection proto-oncogene (RET)]
were present in 23 %.
In the future, most treatment decisions may be based on
the results of comprehensive screening for actionable
molecular abnormalities, making the identification of the
primary site (and the molecular cancer classifier assay)
unnecessary. However, at present the use of both tests is
advisable. Standard treatment for most cancer types still
involves the use of specific regimens of chemotherapy
(±targeted agents) derived empirically, and not guided by
the identification of specific molecular abnormalities. In
addition, clinical data regarding the response of CUP
patients to therapy targeted at molecular abnormalities
identified by screening remains limited [15, 20–22].
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In this report, we document one CUP patient with an
ALK rearrangement who had an excellent response to ALK
inhibition. Additional studies of drugs directed or matched
to a particular genetic alteration are underway in a variety
of solid tumors, including CUP.
5 Conclusion
In this report, we describe a group of CUP patients with
adenocarcinoma of the lung, who were predicted to have
NSCLC by molecular cancer classifier assay; subsequent
testing identified ALK rearrangements in each cancer.
Although further clinical experience is needed, it is rea-
sonable to follow guidelines for the treatment of ALK-
positive lung adenocarcinoma when managing such
patients.
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